Trials of combining insulin with other drugs to control T2D (GLP-1 RA, DDP-4i, and SGLT2i) suggest that such treatment could lead to the use of reduced doses of insulin, less weight gain, and fewer episodes of hypoglycemia compared with the insulin monotherapy. The gene discussed is GLP1R; the disease is Hypoglycemia.